You are here

Wanda Moebius
December 22, 2014

AdvaMed Applauds Outcome Of JCCT In Chicago

WASHINGTON, D.C. – Stephen J. Ubl, president and CEO of the Advanced Medical Technology Association (AdvaMed), today released the following statement in response to the outcome of the 25th U.S.-China Joint Commission on Commerce and Trade (JCCT) in Chicago, Ill., on Dec. 16-18.

“AdvaMed applauds the U.S. and Chinese governments in recognizing the importance of preventing delays in life-saving medical technologies reaching patients that need them. We believe that the commitments reached during the JCCT will result in significant reduction in time-to-market for innovative medical technologies in China while at the same time strengthening regulatory systems to ensure safety and efficacy. AdvaMed stands ready to support both governments in the implementation of these important JCCT commitments.”

The commitments, which call for further acceleration of the expansion of clinical trial product exemption catalogues, comment periods of no less than 60 days for key draft rules and regulations, and enhanced dialogue to promote efficient regulation and market access, are outlined in Office of the U.S. Trade Representative background materials here.

# # #

AdvaMed member companies produce the medical devices, diagnostic products and health information systems that are transforming health care through earlier disease detection, less invasive procedures and more effective treatments. AdvaMed members range from the largest to the smallest medical technology innovators and companies. For more information, visit